Interacciones de Prednisolona

Prednisolona (Orapred, Millipred, Pediapred), corticosteroide, tiene 400 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 29; moderadas: 288; leves: 82; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 1. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (29)

  • Abirateronainhibidor de CYP2D6Grave

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (etiqueta de Abiraterona, Advertencias y precauciones)

  • AdalimumabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

  • AdrenalinasimpaticomiméticoGrave

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (etiqueta de Adrenalina, Interacciones medicamentosas)

  • Arformoterolagonista beta-adrenérgicoGrave

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (etiqueta de Arformoterol, Contraindicaciones)

  • AtazanavirantirretroviralGrave

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (etiqueta de Atazanavir, Interacciones medicamentosas)

  • Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (etiqueta de Axitinib, Advertencias y precauciones)

  • Baricitinibinhibidor de JAKGrave

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Baricitinib, Advertencia en recuadro)

  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (etiqueta de Docetaxel, Advertencias y precauciones)

  • …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (etiqueta de Emtricitabina, rilpivirina y tenofovir, Contraindicaciones)

  • EtanerceptinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Etanercept, Advertencia en recuadro)

  • Formoterolagonista beta-adrenérgicoGrave

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (etiqueta de Formoterol, Contraindicaciones)

  • FosamprenavirantirretroviralGrave

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

  • InfliximabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Infliximab, Advertencia en recuadro)

  • Ketoconazolantifúngico azólicoGrave

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Ketoconazol, Interacciones medicamentosas)

  • LovastatinaestatinaGrave

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (etiqueta de Lovastatina, Contraindicaciones)

  • Mifepristonainhibidor de CYP3A4Grave

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (etiqueta de Mifepristona, Advertencia en recuadro)

  • Mitotanoinductor de CYP3A4Grave

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (etiqueta de Mitotano, Advertencia en recuadro)

  • Moexiprilinhibidor de la ECAGrave

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (etiqueta de Moexipril, Advertencias)

  • RilpivirinaantirretroviralGrave

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (etiqueta de Rilpivirina, Contraindicaciones)

  • Salmeterolagonista beta-adrenérgicoGrave

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (etiqueta de Salmeterol, Advertencia en recuadro)

  • SirolimusinmunosupresorGrave

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (etiqueta de Sirolimus, Advertencias y precauciones)

  • Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (etiqueta de Somatropina, Interacciones medicamentosas)

  • TocilizumabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tocilizumab, Advertencia en recuadro)

  • TofacitinibinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tofacitinib, Advertencia en recuadro)

  • Trandolaprilinhibidor de la ECAGrave

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (etiqueta de Trandolapril, Advertencias)

  • TretinoínaretinoideGrave

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etiqueta de Tretinoína, Advertencia en recuadro)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTGrave

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (etiqueta de Trióxido de arsénico, Advertencia en recuadro)

  • Umeclidinio y vilanterolanticolinérgicoGrave

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (etiqueta de Umeclidinio y vilanterol, Contraindicaciones)

  • UpadacitinibinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Interacciones moderadas (288)

  • AcarbosaantidiabéticoModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ácido acetilsalicílico y dipiridamolantiagregante plaquetarioModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ácido mefenámicoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ácido valproicoanticonvulsivoModerada

    Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (etiqueta de Ácido valproico, Interacciones medicamentosas)

  • Ácido zoledrónicobisfosfonatoModerada

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etiqueta de Ácido zoledrónico, Advertencias y precauciones)

  • AclidinioanticolinérgicoModerada

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (etiqueta de Aclidinio, Interacciones medicamentosas)

  • AfatinibModerada

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etiqueta de Afatinib, Advertencias y precauciones)

  • AlbendazolModerada

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etiqueta de Albendazol, Advertencias y precauciones)

  • AlemtuzumabinmunosupresorModerada

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (etiqueta de Alemtuzumab, Advertencias y precauciones)

  • AlendronatobisfosfonatoModerada

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Alendronato, Advertencias y precauciones)

  • AliskirenoantihipertensivoModerada

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (etiqueta de Aliskireno, Advertencias y precauciones)

  • Alogliptinainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • AlpelisibModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Anfotericina BantifúngicoModerada

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (etiqueta de Anfotericina B, Interacciones medicamentosas)

  • ApixabánanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • ArgatrobánanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Azitromicinaantibiótico macrólidoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • BalsalazidasalicilatoModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • BeclometasonacorticosteroideModerada

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (etiqueta de Beclometasona, Advertencias y precauciones)

  • Belladona y opioopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Belladona y opio, Advertencias y precauciones)

  • BendamustinaModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • BenralizumabModerada

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (etiqueta de Benralizumab, Advertencias y precauciones)

  • Bexagliflozinainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

  • BivalirudinaanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Moderada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Budesonida y formoterolcorticosteroideModerada

    In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

  • BuprenorfinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina y naloxona, Advertencias y precauciones)

  • BupropiónantidepresivoModerada

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (etiqueta de Bupropión, Advertencias y precauciones)

  • Butalbital y paracetamolbarbitúricoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • ButorfanolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butorfanol, Advertencias)

  • Canagliflozinainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CefoxitinacefalosporinaModerada

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (etiqueta de Cefoxitina, Advertencias y precauciones)

  • CelecoxibAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ciprofloxacino, Advertencias y precauciones)

  • CitarabinaantimetabolitoModerada

    These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (etiqueta de Citarabina, Advertencias)

  • CladribinaantimetabolitoModerada

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etiqueta de Cladribina, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • ClobazambenzodiazepinaModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Cocaínaanestésico localModerada

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (etiqueta de Cocaína, Interacciones medicamentosas)

  • CodeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Codeína, Advertencias y precauciones)

  • Colestiraminasecuestrador de ácidos biliaresModerada

    Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DabigatránanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Dapagliflozinainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Dapagliflozina y metforminainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DaptomicinaantibióticoModerada

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (etiqueta de Daptomicina, Advertencias y precauciones)

  • DarunavirantirretroviralModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DenosumabModerada

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DexametasonacorticosteroideModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DicicloverinaanticolinérgicoModerada

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (etiqueta de Dicicloverina, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DiflunisalAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Digoxinaglucósido digitálicoModerada

    Digitalis: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Dulaglutidaagonista del receptor de GLP-1Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • DupilumabModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • EdoxabánanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EfavirenzantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EfedrinasimpaticomiméticoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

  • CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Empagliflozinainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Empagliflozina y metforminainhibidor de SGLT2Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • ErlotinibModerada

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etiqueta de Erlotinib, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EstradiolestrógenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EtodolacoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EtravirinaantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Exenatidaagonista del receptor de GLP-1Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de glicerol, Interacciones medicamentosas)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de sodio, Interacciones medicamentosas)

  • FenilefrinadescongestionanteModerada

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etiqueta de Fenilefrina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FenoprofenoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FentaniloopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Fentanilo, Advertencias y precauciones)

  • Fentermina y topiramatoestimulante del SNCModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Fidaxomicinaantibiótico macrólidoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FingolimodinmunosupresorModerada

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (etiqueta de Fingolimod, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FlunisolidacorticosteroideModerada

    Pregnancy As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at oral doses of 40 and 200 mcg/kg/day, respectively (approximately 2 and 4 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m 2 basis). (etiqueta de Flunisolida, Precauciones)

  • FluocinonidacorticosteroideModerada

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (etiqueta de Fluocinonida, Advertencias y precauciones)

  • FlurbiprofenoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Fluticasona y salmeterolcorticosteroideModerada

    In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Fluticasona y salmeterol, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FulvestrantestrógenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • GlibenclamidasulfonilureaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Glibenclamida y metforminasulfonilureaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • GlimepiridasulfonilureaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • GlipizidasulfonilureaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Glipizida y metforminasulfonilureaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • HalobetasolcorticosteroideModerada

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (etiqueta de Halobetasol, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (etiqueta de Haloperidol, Interacciones medicamentosas)

  • HeparinaanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • HidralazinavasodilatadorModerada

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (etiqueta de Hidralazina, Advertencias)

  • HidrocodonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona, Advertencias y precauciones)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y clorfenamina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y homatropina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y paracetamol, Advertencias)

  • HidromorfonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidromorfona, Advertencias y precauciones)

  • IbandronatobisfosfonatoModerada

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Ibandronato, Advertencias y precauciones)

  • IbuprofenoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • IndometacinaAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Insulina aspartainsulinaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Insulina degludecinsulinaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Insulina detemirinsulinaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Insulina glarginainsulinaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Insulina lisproinsulinaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • IsoniazidaantibióticoModerada

    Antitubercular drugs: Serum concentrations of isoniazid may be decreased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • IvermectinaModerada

    Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (etiqueta de Ivermectina, Advertencias)

  • KetoprofenoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • KetorolacoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • LenacapavirantirretroviralModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • LevofloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Levofloxacino, Advertencias y precauciones)

  • LevonorgestrelprogestágenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • LevorfanolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Levorfanol, Advertencias)

  • Levosalbutamolagonista beta-adrenérgicoModerada

    If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Levosalbutamol, Advertencias y precauciones)

  • Levotiroxinahormona tiroideaModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • Linagliptinainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Linagliptina y metforminainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Liotironinahormona tiroideaModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • Liraglutidaagonista del receptor de GLP-1Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (etiqueta de Lisinopril e hidroclorotiazida, Advertencias)

  • Lopinavir y ritonavirantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Moderada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MargetuximabModerada

    In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (etiqueta de Margetuximab, Advertencias y precauciones)

  • MedroxiprogesteronaprogestágenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MegestrolprogestágenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MeloxicamAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MepolizumabModerada

    Decrease corticosteroids gradually, if appropriate. (etiqueta de Mepolizumab, Advertencias y precauciones)

  • MesalazinasalicilatoModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MetadonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Metadona, Advertencias y precauciones)

  • Metazolamidainhibidor de la anhidrasa carbónicaModerada

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (etiqueta de Metazolamida, Interacciones medicamentosas)

  • MetforminabiguanidaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MetildopaantihipertensivoModerada

    If not, corticosteroids may be given and other causes of anemia should be considered. (etiqueta de Metildopa, Advertencias)

  • MetiltestosteronaandrógenoModerada

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etiqueta de Metiltestosterona, Advertencias)

  • Metimazolfármaco antitiroideoModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • MetiraponaModerada

    This can be corrected by giving appropriate doses of corticosteroids. (etiqueta de Metirapona, Advertencias y precauciones)

  • MetohexitalbarbitúricoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Metolazonadiurético tiazídicoModerada

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (etiqueta de Metolazona, Interacciones medicamentosas)

  • MetotrexatoinmunosupresorModerada

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (etiqueta de Metotrexato, Interacciones medicamentosas)

  • MicafunginaantifúngicoModerada

    Effect of Micafungin in Sodium Chloride Injection on Other Drugs CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. (etiqueta de Micafungina, Interacciones medicamentosas)

  • MiglitolantidiabéticoModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Moderada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • MometasonacorticosteroideModerada

    Lung function (FEV 1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (etiqueta de Mometasona, Advertencias y precauciones)

  • Montelukastantagonista de los receptores de leucotrienosModerada

    Inhaled corticosteroid may be reduced gradually. (etiqueta de Montelukast, Advertencias y precauciones)

  • MorfinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Morfina, Advertencias y precauciones)

  • MoxifloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Moxifloxacino, Advertencias y precauciones)

  • NabumetonaAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NalbufinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Nalbufina, Advertencias)

  • Naltrexona y bupropiónantagonista opioideModerada

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (etiqueta de Naltrexona y bupropión, Advertencias y precauciones)

  • NaproxenoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NatalizumabinmunosupresorModerada

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (etiqueta de Natalizumab, Advertencias y precauciones)

  • NateglinidameglitinidaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NevirapinaantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NintedanibModerada

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etiqueta de Nintedanib, Advertencias y precauciones)

  • Nirmatrelvir y ritonavirantiviralModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • NoretisteronaprogestágenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • OcrelizumabinmunosupresorModerada

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (etiqueta de Ocrelizumab, Advertencias y precauciones)

  • OfloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ofloxacino, Advertencias)

  • OliceridinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oliceridina, Advertencias y precauciones)

  • OmalizumabModerada

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (etiqueta de Omalizumab, Advertencias y precauciones)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • OxaprozinaAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • OxicodonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona y paracetamol, Advertencias y precauciones)

  • OximorfonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oximorfona, Advertencias y precauciones)

  • Palbociclibinhibidor de CYP3A4Moderada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • PamidronatobisfosfonatoModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Paracetamol y codeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Paracetamol y codeína, Advertencias)

  • PasireotidaModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • PenicilaminaModerada

    Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

  • Pentazocina y naloxonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Pentazocina y naloxona, Advertencias)

  • PerampanelanticonvulsivoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Petidina (meperidina)opioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Petidina (meperidina), Advertencias y precauciones)

  • PioglitazonatiazolidinedionaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Pioglitazona y metforminatiazolidinedionaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • PiroxicamAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • PonesimodinmunosupresorModerada

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (etiqueta de Ponesimod, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • PrednisonacorticosteroideModerada

    Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (etiqueta de Prednisona, Advertencias y precauciones)

  • PrimidonaanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • ProgesteronaprogestágenoModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Prometazina y codeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Prometazina y codeína, Advertencias y precauciones)

  • Propiltiouracilofármaco antitiroideoModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • Propofoldepresor del SNCModerada

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (etiqueta de Propofol, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RepaglinidameglitinidaModerada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RifabutinaantibióticoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RisedronatobisfosfonatoModerada

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etiqueta de Risedronato, Advertencias y precauciones)

  • RitonavirantirretroviralModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • RivaroxabánanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Rocuroniobloqueador neuromuscularModerada

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (etiqueta de Rocuronio, Advertencias y precauciones)

  • Salbutamolagonista beta-adrenérgicoModerada

    If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Salbutamol, Advertencias y precauciones)

  • SalsalatoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Saxagliptinainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Saxagliptina y metforminainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Semaglutidaagonista del receptor de GLP-1Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Sitagliptinainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Sitagliptina y metforminainhibidor de la DPP-4Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Subsalicilato de bismutosalicilatoModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • SulfasalazinasulfonamidaModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • SulindacoAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Sumatriptán y naproxenotriptánModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Suxametonio (succinilcolina)bloqueador neuromuscularModerada

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (etiqueta de Suxametonio (succinilcolina), Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Moderada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • TapentadolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tapentadol, Advertencias y precauciones)

  • TemozolomidaModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • TemsirolimusModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TeofilinametilxantinaModerada

    Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (etiqueta de Teofilina, Advertencias)

  • Terbutalinaagonista beta-adrenérgicoModerada

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (etiqueta de Terbutalina, Advertencias)

  • Teriparatidahormona tiroideaModerada

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (etiqueta de Prednisolona, Advertencias y precauciones)

  • TesamorelinaModerada

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (etiqueta de Tesamorelina, Interacciones medicamentosas)

  • TestosteronaandrógenoModerada

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (etiqueta de Testosterona, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • TiotropioanticolinérgicoModerada

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (etiqueta de Tiotropio, Interacciones medicamentosas)

  • Tirzepatidaagonista del receptor de GLP-1Moderada

    Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • TolmetinaAINEModerada

    NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoModerada

    CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Torasemidadiurético de asaModerada

    Corticosteroids and ACTH: Increased risk of hypokalemia. (etiqueta de Torasemida, Interacciones medicamentosas)

  • TramadolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol, Advertencias y precauciones)

  • Tramadol y paracetamolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol y paracetamol, Advertencias y precauciones)

  • TrastuzumabModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (etiqueta de Triamtereno e hidroclorotiazida, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • WarfarinaanticoagulanteModerada

    Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (etiqueta de Zenocutuzumab, Advertencias y precauciones)

Menciones leves (82)

  • Acetazolamidainhibidor de la anhidrasa carbónicaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ácido bempedoicoinhibidor de OATP1B1Leve

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (etiqueta de Ácido bempedoico, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (etiqueta de Alteplasa, Advertencias y precauciones)

  • AmikacinaaminoglucósidoLeve

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Amikacina, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Ampicilinaantibiótico del grupo de las penicilinasLeve

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Ampicilina, Advertencias)

  • Anfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina, Interacciones medicamentosas)

  • Anfetamina y dexanfetaminaestimulante del SNCLeve

    Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina y dexanfetamina, Interacciones medicamentosas)

  • Atenolol y clortalidonabetabloqueanteLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Benazepril e hidroclorotiazidainhibidor de la ECALeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etiqueta de Bevacizumab, Advertencias y precauciones)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Bumetanidadiurético de asaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (etiqueta de Busulfano, Advertencias)

  • Calcitriolanálogo de la vitamina DLeve

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (etiqueta de Calcitriol, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Cannabidiol (con receta)anticonvulsivoLeve

    Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (etiqueta de Cannabidiol (con receta), Advertencias y precauciones)

  • CefaclorcefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefaclor, Advertencias)

  • CefadroxilocefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefadroxilo, Advertencias y precauciones)

  • CefdinircefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefdinir, Advertencias)

  • CefotetáncefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefotetán, Advertencias)

  • CefprozilocefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefprozilo, Advertencias)

  • CeftazidimacefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Ceftazidima, Advertencias)

  • CeftriaxonacefalosporinaLeve

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (etiqueta de Ceftriaxona, Advertencias y precauciones)

  • ClofarabinaantimetabolitoLeve

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (etiqueta de Clofarabina, Advertencias y precauciones)

  • Clomifenomodulador selectivo de los receptores de estrógenosLeve

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (etiqueta de Clomifeno, Advertencias)

  • Clorotiazidadiurético tiazídicoLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Clortalidonadiurético tiazídicoLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (etiqueta de Corticotropina, Advertencias y precauciones)

  • Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Dexanfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

  • Donepeziloinhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Droperidolantagonista de la dopaminaLeve

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (etiqueta de Droperidol, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECALeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Eplerenonaantagonista de la aldosteronaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Espironolactonaantagonista de la aldosteronaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Fisostigminainhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • FludarabinaantimetabolitoLeve

    Steroids may or may not be effective in controlling these hemolytic episodes. (etiqueta de Fludarabina, Advertencias y precauciones)

  • FludrocortisonacorticosteroideLeve

    Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (etiqueta de Prednisolona, Advertencias y precauciones)

  • FluoxetinaISRSLeve

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Fluoxetina, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECALeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Furosemidadiurético de asaLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Galantaminainhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

  • GuselkumabinmunosupresorLeve

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Guselkumab, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • HidrocortisonacorticosteroideLeve

    Amphotericin B: There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see also Potassium depleting agents). (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Indapamidadiurético tiazídicoLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • IpratropioanticolinérgicoLeve

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etiqueta de Lenalidomida, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (etiqueta de Melfalán, Advertencias)

  • Memantina y donepeziloinhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Metanfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Metanfetamina, Interacciones medicamentosas)

  • Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Midodrinaagonista alfa-adrenérgicoLeve

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (etiqueta de Midodrina, Interacciones medicamentosas)

  • Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • Naltrexonaantagonista opioideLeve

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (etiqueta de Naltrexona, Advertencias y precauciones)

  • Neostigminainhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Olanzapina y fluoxetinaantipsicóticoLeve

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Oxacilinaantibiótico del grupo de las penicilinasLeve

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (etiqueta de Oxacilina, Advertencias)

  • Penicilina Gantibiótico del grupo de las penicilinasLeve

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (etiqueta de Penicilina G, Advertencias)

  • Penicilina Vantibiótico del grupo de las penicilinasLeve

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Penicilina V, Advertencias)

  • Piridostigminainhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECALeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • QuininaantipalúdicoLeve

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (etiqueta de Quinina, Interacciones medicamentosas)

  • Raloxifenomodulador selectivo de los receptores de estrógenosLeve

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Raloxifeno, Interacciones medicamentosas)

  • RituximabinmunosupresorLeve

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etiqueta de Rituximab, Advertencias y precauciones)

  • Rivastigminainhibidor de la colinesterasaLeve

    Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (etiqueta de Tenecteplasa, Advertencias y precauciones)

  • TobramicinaaminoglucósidoLeve

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

  • Triamterenodiurético ahorrador de potasioLeve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • UstekinumabinmunosupresorLeve

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (etiqueta de Ustekinumab, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • Vitamina DVitaminas y mineralesLeve

    Los corticosteroides como la prednisona reducen la absorción de calcio y alteran el metabolismo de la vitamina D, lo que contribuye a la pérdida de masa ósea. (NIH Office of Dietary Supplements, Vitamin D)

  • ZiprasidonaantipsicóticoLeve

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Ziprasidona, Advertencias y precauciones)

Sin interacción significativa según la etiqueta (1)

  • AminofilinametilxantinaSin interacción

    …vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline tocainide… (etiqueta de Aminofilina, Interacciones medicamentosas)

Compruebe Prednisolona frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.